Browse our 650+ Publications​

Latest Publications

Epcoritamab in relapsed/refractory large B-cell lymphoma:2-year follow-up from the pivotal EPCORE NHL-1 trial

Thieblemont C, et al.
Leukemia
September 2024
Authors and Affiliates
Catherine Thieblemont 1✉, Yasmin H. Karimi2, Herve Ghesquieres3, Chan Y. Cheah4, Michael Roost Clausen5, David Cunningham6, Wojciech Jurczak 7, Young Rok Do8, Robin Gasiorowski 9, David John Lewis10, Tae Min Kim 11, Marjolein van der Poel12, Michelle Limei Poon13, Tatyana Feldman14, Kim M. Linton15, Anna Sureda 16, Martin Hutchings17, Minh H. Dinh 18, Nurgul Kilavuz19, David Soong19, Thomas Mark20, Mariana Sacchi19, Tycel Phillips21,23 and Pieternella J. Lugtenburg22 1Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France. 2Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. 3Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. 4Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia. 5Vejle Hospital, Vejle, Denmark. 6The Royal Marsden NHS Foundation Trust, Sutton, UK. 7MSC National Research Institute of Oncology, Kraków, Poland. 8Keimyung University Dongsan Medical Center, Daegu, Republic of Korea. 9Concord Hospital, University of Sydney, Sydney, Australia. 10University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK. 11Seoul National University Hospital, Seoul, Republic of Korea. 12Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. 13National University Hospital, Singapore, Singapore. 14John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA. 15The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK. 16Clinical Hematology Department, Institut Català d’Oncologia – L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain. 17Rigshospitalet and University of Copenhagen, Copenhagen, Denmark. 18AbbVie, North Chicago, IL, USA. 19Genmab, Plainsboro, NJ, USA. 20Genmab, Copenhagen, Denmark. 21University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. 22Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, University Medical Center, Rotterdam, The Netherlands. 23Present address: City of Hope, Duarte, CA, USA. ✉email: catherine.thieblemont@aphp.fr

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma(MOLTO): a multicentre, single-arm, phase 2 trial

Tedeschi A, et al.
Lancet Oncology
September 2024
Authors and Affiliates
Alessandra Tedeschi*, Anna Maria Frustaci*, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta, Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valentina Griggio, Georg Stüssi, Angelica Calleri, Katia Pini, Roberto Cairoli, Thorsten Zenz, Alessio Signori, Emanuele Zucca, Davide Rossi, Marco Montillo Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy (A Tedeschi MD, A M Frustaci MD, M Deodato MD, R Cairoli MD, M Montillo MD); Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland (A Condoluci MD, Prof D Rossi MD, K Pini BS, Prof E Zucca MD); Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland (A Condoluci, Prof D Rossi, Prof G Stüssi MD, Prof E Zucca MD); University Division of Hematology, AOU Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy (R Jones MD, V Griggio PhD); Department of Oncology ASST Sette Laghi,\ Ospedale di Circolo, Varese, Italy (Prof M Coscia MD);Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy (Prof R Chiarle MD, V Tabanelli MD, A Calleri PhD); Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy (Prof R Chiarle); Department of Pathology, Boston Children’s Hospital, Boston, MA, USA (Prof R Chiarle); Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “L e A Seràgnoli”, Bologna, Italy

Longitudinal study of immunity to SARS-CoV2 inocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination

Kister I., et al.
Annals of Clinical and Translational Neurology
August 2024
Authors and Affiliates
Ilya Kister, Ryan Curtin, Amanda L. Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E. Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva, Marie I. Samanovic, Mark J. Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Michelle Krogsgaard & Gregg J. Silverman

Case report of fatal immune-mediatedmyocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependentCD28 costimulator and dualPD-L1/CTLA-4checkpoint inhibitor, incombination with pembrolizumab

Cavalcante L., et al.
Journal for ImmunoTherapy of Cancer
August 2024
Authors and Affiliates
Ludimila Cavalcante, Sreenivasa Chandana, Nehal Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar.

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Touzeau C, et al.
Blood
August 2024
Authors and Affiliates
Cyrille Touzeau (University hospital, France) Amrita Krishnan (City of Hope Comprehensive Cancer Center, United States) Philippe Moreau (Hematology, University Hospital Hôtel-Dieu, France) Aurore Perrot (CHU Toulouse - IUCT Oncopole, France) Saad Usmani (Memorial Sloan Kettering Cancer Center, United States) Salomon Manier (CHU Lille, France) Michele Cavo (Seràgnoli Institute of Hematology; Bologna University School of Medicine, Bologna, Italy, Italy) Carmen Martinez Chamorro (Hospital Universitario Quirón Pozuelo, Spain) Ajay Nooka (Emory University Winship Cancer Institute, United States) Thomas Martin (UCSF, United States) Lionel Karlin (Hôpital Lyon Sud, France) Xavier Leleu (Hopital La Miletrie, France) Nizar Bahlis (Arnie Charbonneau Cancer Institute, University of Calgary, Canada) Britta Besemer (University Hospital of Tuebingen, Germany) Lixia Pei (Janssen R&D, United States) Sarah Stein (Janssen R&D US, United States) Shun Xin Wang Lin (Janssen Research & Development, United States) Danielle Trancucci (Janssen Research & Development, United States) Raluca Verona (Janssen Research & Development, United States) Suzette Girgis (Janssen Research & Development, LLC, United States) Xin Miao (Janssen Research & Development, LLC, United States) Clarissa Uhlar (Janssen R&D, United States) Katherine Chastain (Janssen Research & Development, LLC, United States) Alfred Garfall (University of Pennsylvania, United States)

Measurable residual disease (MRD) dynamics in multiple myeloma and the influence of clonal diversity analyzed by artificial intelligence

Martinez-Lopez J, et al.
Blood Cancer Journal
August 2024
Authors and Affiliates
J. Martinez-Lopez 1,2, N. Lopez-Muñoz 1, A. Chari 2, S. Dorado 3, S. Barrio1, S. Arora2, A. Kumar2, A. Chung2, T. Martin 2 and J. Wolf2 1Hematology Department, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain. 2Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 3Medical Department, Altum Sequencing, Madrid, Spain.

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

Suvannasankha A, et al.
Cancer
August 2024
Authors and Affiliates
Attaya Suvannasankha MD1 | Nizar Bahlis MD2 | Suzanne Trudel MSc, MD3 | Katja Weisel MD4 | Christian Koenecke MD5 | Albert Oriol MD, PhD6 | Peter M. Voorhees MD7 | Aranzazu A. Alonso MD8 | Natalie S. Callander MD9 | María‐Victoria Mateos MD, PhD10 | Nishitha Reddy MD11 | Shawn Hakim PhD12 | John LaMacchia MD, PhD13 | Nashita Patel MSc, PhD14 | Danaé Williams MSc12 | Roxanne C. Jewell PhD15 | Xiangdong Zhou PhD12 | Ira Gupta MD16 | Joanna Opalinska MD12 | Ajay K. Nooka MD, MPH, FACP17 1 Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, Indiana, USA 2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada 3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada 4 University Medical Center Hamburg‐Eppendorf, Hamburg, Germany 5 Hannover Medical School, Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany 6 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain 7 Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA 8 Hospital Universitario Quirónsalud Madrid, Madrid, Spain 9 Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA 10Instituto de Investigación Biomédica de Salamanca and Centro de Investigación del Cáncer, Hospital Universitario de Salamanca, Salamanca, Spain 11Merck & Co., Inc, Rahway, New Jersey, USA 12GlaxoSmithKline, Upper Providence, Pennsylvania, USA 13GlaxoSmithKline, Waltham, Massachusetts, USA 14GlaxoSmithKline, Stevenage, UK 15GlaxoSmithKline, Durham, North Carolina, USA 16GlaxoSmithKline, Philadelphia, Pennsylvania, USA 17Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia, USA

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

Schneider-Hohendorf, et al.
Brain
July 2024
Authors and Affiliates
Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer, Sven G. Meuth, Orhan Aktas, Martin W. Hümmert, Julian R. Kretschmer, Corinna Trebst, Ilka Kleffner, Jennifer Massey, Paolo A. Muraro, Haiyin Chen-Harris, Catharina C. Gross, Luisa Klotz, Heinz Wiendl and Nicholas Schwab

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Chari A, et al.
Blood Cancer Journal
July 2024
Authors and Affiliates
Ajai Chari 1,22✉, Jonathan L. Kaufman 2, Jacob Laubach 3, Douglas W. Sborov4, Brandi Reeves 5, Cesar Rodriguez1, Rebecca Silbermann6, Luciano J. Costa 7, Larry D. Anderson Jr 8, Nitya Nathwani9, Nina Shah10, Naresh Bumma11, Sarah A. Holstein 12, Caitlin Costello13, Andrzej Jakubowiak 14, Tanya M. Wildes12, Robert Z. Orlowski 15, Kenneth H. Shain16, Andrew J. Cowan17, Huiling Pei18, Annelore Cortoos19, Sharmila Patel19, Thomas S. Lin19, Peter M. Voorhees 20✉, Saad Z. Usmani 21✉ and Paul G. Richardson 1Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2Winship Cancer Institute, Emory University, Atlanta, GA, USA. 3Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. 4Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. 5University of North Carolina–Department of Medicine–Chapel Hill, Chapel Hill, NC, USA. 6Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. 7University of Alabama at Birmingham, Birmingham, AL, USA. 8Myeloma, Waldenstrӧm’s and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. 9Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 10University of California San Francisco, San Francisco, CA, USA. 11Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 12Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 13Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. 14University of Chicago Medical Center, Chicago, IL, USA. 15Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 16Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA. 17Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA. 18Janssen Research & Development, LLC, Titusville, NJ, USA. 19Janssen Scientific Affairs, LLC, Horsham, PA, USA. 20Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA. 21Memorial Sloan Kettering Cancer Center, New York, NY, USA. 22Affiliation at the time of study conduct.

A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia

Srinagesh H, et al.
Blood
July 2024
Authors and Affiliates
Hrishikesh Srinagesh1 , Clayton Jackson2 , Parveen Shiraz3 , Nikeshan Jeyakumar1 , Mark Hamilton1 , Emily Egeler4 , Sharon Mavroukakis4 , Adam Kuo4 , Juancarlos Cancilla4 , Bita Sahaf4 , Neha Agarwal3 , Alyssa Kanegai3 , Anne Marijn Kramer3,4 , Sally Arai3 , Sushma Bharadwaj3 , Saurabh Dahiya3 , Hitomi Hosoya3 , Laura Johnston3 , Vanessa Kennedy3 , Michaela Liedtke1 , Robert Lowsky3 , Lekha Mikkilineni3 , Robert Negrin3 , Andrew Rezvani3 , Surbhi Sidana3 , Judith Shizuru3 , Melody Smith3 , Wen-Kai Weng3 , Steven Feldman4 , Matthew J. Frank3,4 , Zachary Lee5 , Mary Tagliaferri5 , A. Mario Marcondes5 , David Miklos3,4 , Crystal Mackall4 , Lori Muffly3,4 Division of Hematology/Oncology, UT Southwestern, Dallas, TX; 3 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford CA; 4 Center for Cancer Cell Therapy, Stanford University, Stanford, CA; 5 Nektar Therapeutics, San Francisco, CA
Previous Next